From the Wall Street Journal:


    Eli Lilly & Co. said Wednesday it would plead guilty to a misdemeanor violation of the Food, Drug and Cosmetic Act and pay $36 million to settle charges of off-label promotion of its Evista osteoporosis treatment in 1998.


    Government regulators charged the company with promoting its Evista product for two other uses -- the prevention of breast cancer and for reducing cardiovascular risk -- neither of which have been approved by the Food and Drug Administration.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish